Oppenheimer Asset Management Inc. Increases Holdings in Certara, Inc. (NASDAQ:CERT)

Oppenheimer Asset Management Inc. increased its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 25.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 221,550 shares of the company's stock after buying an additional 44,270 shares during the period. Oppenheimer Asset Management Inc. owned about 0.14% of Certara worth $2,193,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Certara by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company's stock worth $132,455,000 after acquiring an additional 38,068 shares during the period. ArrowMark Colorado Holdings LLC lifted its holdings in Certara by 164.2% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock valued at $66,171,000 after purchasing an additional 3,861,674 shares during the last quarter. Teacher Retirement System of Texas boosted its position in Certara by 13.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company's stock worth $48,542,000 after purchasing an additional 557,348 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Certara by 4.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company's stock worth $43,494,000 after purchasing an additional 182,042 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its stake in shares of Certara by 63.8% in the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock worth $40,668,000 after purchasing an additional 1,487,998 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. KeyCorp increased their target price on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Finally, Robert W. Baird boosted their price objective on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $15.67.

Certara Price Performance

Shares of CERT traded up $0.32 during mid-day trading on Monday, reaching $11.70. 2,953,668 shares of the stock traded hands, compared to its average volume of 1,440,209. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -585.00 and a beta of 1.45. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $16.93. The firm has a fifty day moving average price of $11.88 and a 200 day moving average price of $11.85. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The business had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. During the same period in the previous year, the business earned $0.10 earnings per share. The firm's revenue was up 9.7% on a year-over-year basis. As a group, equities research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.